Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia

被引:32
作者
Barter, Philip [1 ]
McPherson, Y. Ruth
Song, Kijoung
Kesaniemi, Y. Antero
Mahley, Robert
Waeber, Gerard
Bersot, Thomas
Mooser, Vincent
Waterworth, Dawn
Grundy, Scott M.
机构
[1] Heart Res Inst, Sydney, NSW 2050, Australia
[2] Univ Ottawa, Ottawa, ON K1Y 4W7, Canada
[3] GlaxoSmithKline, Collegeville, PA 19406 USA
[4] Univ Oulu, Dept Internal Med & Bioctr, FIN-90014 Oulu, Finland
[5] Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94158 USA
[6] Univ Lausanne Hosp, Dept Med, Lausanne, Switzerland
[7] Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75235 USA
关键词
D O I
10.1210/jc.2006-2219
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: The worldwide epidemic of overweight and obesity is setting the scene for a new wave of premature cardiovascular disease. Objective: The objective of this study was to define relationships between dyslipidemia and other metabolic abnormalities in overweight subjects. Design: This study included comparison of overweight subjects with and without dyslipidemia. Setting: The setting was an institutional practice. Patients: Dyslipidemic subjects (n = 715) had plasma triglyceride greater than or equal to the 75th percentile in combination with high-density lipoprotein cholesterol (HDL-C) less than or equal to the 25th percentile. Unrelated, normolipidemic controls (n = 1073) had HDL-C higher than the median and triglyceride lower than the median. It was a requirement for the control subjects to have a body mass index (BMI) greater than 25 kg/m2. Main Outcome Measures: The main outcome measures included BMI, inflammatory markers, adipokines, blood pressure, and fasting plasma glucose and insulin. Results: The mean BMI in the subjects and controls was 28.7 and 28.2 kg/m(2), respectively. Subjects had higher levels of plasma high-sensitivity C-reactive protein (3.0 vs. 2.0 mg/liter; P < 0.001), lower levels of adiponectin (4.7 vs. 6.6 mg/liter; P < 0.001), and, after adjustment for age, BMI, gender, smoking, statin, and beta-blocker use, higher systolic (P = 0.001) and diastolic (P = 0.05) blood pressures. Fasting plasma glucose, insulin, and homeostasis model of assessment-insulin resistance were all significantly higher in subjects than controls (P < 0.0001). Conclusions: Identification of people solely on the basis of an elevated plasma triglyceride and a low HDL-C uncovers an overweight group of people who have a generalized metabolic disorder. In contrast, overweight people with normal plasma lipids have normal glucose and insulin metabolism, low levels of inflammatory markers, and normal blood pressure. Such people may thus be at relatively low risk of developing diabetes and cardiovascular disease despite being overweight.
引用
收藏
页码:2041 / 2045
页数:5
相关论文
共 24 条
[1]   The obesity epidemic and its cardiovascular consequences [J].
Behn, Agnieszka ;
Ur, Ehud .
CURRENT OPINION IN CARDIOLOGY, 2006, 21 (04) :353-360
[2]   Medical consequences of obesity [J].
Bray, GA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (06) :2583-2589
[3]   Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease [J].
Dagenais, GR ;
Yi, QL ;
Mann, JFE ;
Bosch, J ;
Pogue, J ;
Yusuf, S .
AMERICAN HEART JOURNAL, 2005, 149 (01) :54-60
[4]   Metabolic syndrome - A comprehensive perspective based on interactions between obesity, diabetes, and inflammation [J].
Dandona, P ;
Aljada, A ;
Chaudhuri, A ;
Mohanty, P ;
Garg, R .
CIRCULATION, 2005, 111 (11) :1448-1454
[5]   Is visceral obesity the cause of the metabolic syndrome? [J].
Després, JP .
ANNALS OF MEDICINE, 2006, 38 (01) :52-63
[6]   Prevention conference VII -: Obesity, a Worldwide Epidemic Related to Heart Disease and Stroke -: Executive summary [J].
Eckel, RH ;
York, DA ;
Rössner, S ;
Hubbard, V ;
Caterson, I ;
St Jeor, ST ;
Hayman, LL ;
Mullis, RM ;
Blair, SN .
CIRCULATION, 2004, 110 (18) :2968-2975
[7]   The metabolic syndrome [J].
Eckel, RH ;
Grundy, SM ;
Zimmet, PZ .
LANCET, 2005, 365 (9468) :1415-1428
[8]   Obesity and coronary heart disease [J].
Garrison, RJ ;
Higgins, MW ;
Kannel, WB .
CURRENT OPINION IN LIPIDOLOGY, 1996, 7 (04) :199-202
[9]   Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [J].
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, R ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Cleeman, JI ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ ;
Keller, SA ;
Jehle, AJ .
CIRCULATION, 2002, 106 (25) :3143-3421
[10]   Analysis of obesity and Hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study [J].
Han, TS ;
Williams, K ;
Sattar, N ;
Hunt, KJ ;
Lean, MEJ ;
Haffner, SM .
OBESITY RESEARCH, 2002, 10 (09) :923-931